Lantern Pharma announced the appointment of two new members, Franklyn Prendergast, MD, Ph.D. and Vijay Chandru, Ph.D. to its board of directors. In addition, Dr. Jeffrey Keyser, JD, MPH, Ph.D., will continue in his role as chairman of Lantern Pharma’s Board of Directors. Alongside Dr. Keyser and other board members, Dr. Prendergast and Dr. Chandru bring significant clinical, scientific and technological depth, specifically in oncology, genomics and corporate development. Lantern Pharma expects their capabilities to complement its existing leadership as the company evolves. Franklyn Prendergast, MD, Ph.D. has held numerous leadership positions throughout his medical career, including serving as Director of the Mayo Clinic Comprehensive Care Center and Director of the Mayo Clinic Center for Individualized Medicine in Rochester, MN, the world’s first and largest integrated nonprofit medical group practice. He has held board positions at Eli Lily, Cancer Genetics Inc., the International Medica Foundation, and the Infectious Disease Research Institute, and also held positions at the National Institutes of Health, National Advisory General Medical Sciences Council and National Cancer Institute. In addition to serving on the Board of Directors at Eli Lily for 22 years, he also served on the Audit Committee at Eli Lily for 13 of those years. Vijay Chandru, Ph.D. is a bioinformatics pioneer, and is Co-founder and Director of Strand Life Sciences. He is a Fellow of the National Academies of Science and Engineering in Asia, a 2006 World Economic Forum Technology Pioneer, a member of the World Economic Forum council on the future of the health sector and a member of the expert committee on innovation and entrepreneurship at the National Institution for Transforming India. In addition, Dr. Chandru advises a variety of AI and tech startups across multiple industry sectors. Jeffrey Keyser, JD, MPH, Ph.D. has once again been appointed Lantern Pharma’s Board Chairman and brings decades of experience in cancer therapeutics. He is the founder, President and Chief Operating Officer of Renibus Therapeutics, and previously served as Chief Operating Officer of ZS Pharma.